MedTrace Logo

Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function

NCT03933618 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

This study evaluates anastrazole and clomiphene in the improvement in hypogonadal symptoms and erectile function. Each subject will receive Anastrazole 1 mg/day, clomiphene 25 mg/day and placebo in randomized schedule of 8 week intervals.

Conditions

  • Hypogonadism, Male

Interventions

DRUG

Anastrozole 1mg

DRUG

Clomiphene Citrate 25mg

DRUG

Placebo - Cap

Sponsors & Collaborators

  • Laboratory Corporation of America

    collaborator INDUSTRY

  • Albany Medical College

    lead OTHER

Principal Investigators

  • Robert C Welliver, MD · Albany Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-02
Primary Completion
2017-03-08
Completion
2017-03-08

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03933618 on ClinicalTrials.gov